Also trades as: ESLA (NASDAQ) · $vol 0M
ESLAW NASDAQ
Estrella Immunopharma, Inc.
1W: -50.8%
1M: -32.8%
3M: +28.0%
YTD: -28.9%
1Y: -8.6%
$0.06
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$33.6M
52W Range0.064-0.11
Volume0
Avg Volume6,939
Beta-0.09
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOCheng Liu
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2023-10-02
Websiteestrellabio.com
5858 Horton Street
EmeryVille, CA 94608
US
EmeryVille, CA 94608
US
510 318 9098
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Xu Jiandong | P-Purchase | 1,000 | $1.33 | 2025-10-07 |
| Xu Jiandong | P-Purchase | 1,000 | $1.16 | 2025-09-22 |
| Jia Dengyao | 0 | — | 2025-09-22 | |
| Xu Jiandong | P-Purchase | 100 | $1.04 | 2025-09-11 |
| Liu Cheng | A-Award | 509,204 | $0.81 | 2024-10-30 |